3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Carcinoma, Hepatocellular
5
Leukemia, Myeloid, Acute
3
Uveal Melanoma
2
Stomach Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Liver Neoplasms
1
Leiomyosarcoma
1
HER2 Negative Metastatic Breast Cancer
1
Glioma
1
Glioblastoma
1
Colorectal Neoplasms
1
Carcinoma
1
Advanced Solid Cancers
1
Advanced Pancreatic Cancer
1
Interventions
Carboplatin
30
Cisplatin
23
pembrolizumab
22
Paclitaxel
21
Pemetrexed
20
Gemcitabine
10
osimertinib
9
durvalumab
9
Nivolumab
9
130-nm albumin-bound paclitaxel
8
Sunitinib
7
Sorafenib
7
Fluorouracil
7
Everolimus
7
Docetaxel
7
Axitinib
7
Cetuximab
6
epothilone B
5
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
5
volociximab
4
trebananib
4
reolysin
4
catumaxomab
4
cabozantinib
4
atezolizumab
4
Radiotherapy
4
Ipilimumab
4
vosaroxin
3
liposomal doxorubicin
3
lenvatinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma
×
ADI PEG20
×
Clear all
NCT02029690
2020-09-25
TRAP
Polaris Group
Phase 1
Terminated
85 enrolled